**Post-licensure deployment of oral cholera vaccines: a systematic review**

Stephen Martin, Anna Lena Lopez, Anna Bellos, Jacqueline Deen, Mohammad Ali, Kathryn Alberti, Dang Duc Anh, Alejandro Costa, Rebecca F Grais, Dominique Legros, Francisco J Luquero, Megan B Ghai, William Perea & David A Sack

**Objective** To describe and analyse the characteristics of oral cholera vaccination campaigns; including location, target population, logistics, vaccine coverage and delivery costs.

**Methods** We searched PubMed, the World Health Organization (WHO) website and the Cochrane database with no date or language restrictions. We contacted public health personnel, experts in the field and in ministries of health and did targeted web searches.

**Findings** A total of 33 documents were included in the analysis. One country, Viet Nam, incorporates oral cholera vaccination into its public health programme and has administered approximately 10.9 million vaccine doses between 1997 and 2012. In addition, over 3 million doses of the two WHO pre-qualified oral cholera vaccines have been administered in more than 16 campaigns around the world between 1997 and 2014. These campaigns have either been pre-emptive or reactive and have taken place under diverse conditions, such as in refugee camps or natural disasters. Estimated two-dose coverage ranged from 46 to 88% of the target population. Approximate delivery cost per fully immunized person ranged from 0.11–3.99 United States dollars.

**Conclusion** Experience with oral cholera vaccination campaigns continues to increase. Public health officials may draw on this experience and conduct oral cholera vaccination campaigns more frequently.

**Abstracts in** العربية, 中文, Français, Русский and Español at the end of each article.

---

**Introduction**

*Vibrio cholerae* O1 and O139 causes severe diarrhoea and the main strategies to prevent the disease are to promote hygiene and to ensure safe water and sanitation. These basic needs are often not met in endemic areas with seasonal cholera outbreaks or during man-made or natural disasters in impoverished areas. An additional tool for cholera prevention and control is the oral cholera vaccine. In October 2009, the World Health Organization (WHO) Strategic Advisory Group of Experts on immunization recommended that oral cholera vaccination should be considered as a reactive strategy during outbreaks, in addition to the already recommended preventive use of oral cholera vaccine in endemic areas. A vaccine stockpile was created in 2012, with an initial two million doses to be available mainly for epidemic response in low-income countries. In November 2013, the global alliance for vaccines and immunizations (Gavi Alliance) approved a financial contribution towards the stockpile to expand its use. With the availability of the oral cholera vaccine stockpile, more governments might consider cholera vaccination where needed.

A monovalent inactivated vaccine containing killed whole-cells of *V. cholerae* serogroup O1 and the B-subunit of cholera toxin was the first oral cholera vaccine to obtain international licensure in 1991 and WHO prequalification in 2001. The vaccine is marketed as Dukoral® (Crucell, Netherlands). Randomized, placebo-controlled trials of earlier versions of Dukoral® in Bangladesh and the current recombinant B-subunit whole cell vaccine in Peru showed that the vaccine is safe and confers an initial protection of approximately 85% in the first months. Follow-up studies in Bangladesh estimated a 62% protection during the first year, 57% during the second year and negligible thereafter.

During the mid-1980s, the National Institute of Hygiene and Epidemiology in Viet Nam developed an oral cholera vaccine for the country’s public health programme. A two-dose regimen of a first-generation of monovalent (anti-O1) cholera vaccine had an estimated efficacy of 66% against the El Tor strain of *V. cholerae*. In 1997, the vaccine was augmented with killed *V. cholerae* serogroup O139 whole cells to create a bivalent vaccine, which was locally licensed as ORC-Vax™ (Vabiotech, Viet Nam). After changing production procedures in 2009, the vaccine was reformulated and licensed as mORC-Vax™ (Vabiotech, Viet Nam) and is currently used in Viet Nam’s public health programme. However, the vaccine is not pre-qualified by WHO.

To make the mORC-Vax™ internationally available, manufacture of the reformulated vaccine was transferred to Shantha Biotechnics Ltd in India, where the national regulatory authority is approved by WHO. This led to the development of Shanchol™, which is the third currently-available oral cholera vaccine. A randomized, placebo-controlled trial in India showed that Shanchol™ is safe and confers 67% protective efficacy against cholera within two years of vaccination, 66% at three years and 65% at five years of follow-up. Shanchol™ was licensed in India in 2009 and received WHO pre-qualification in 2011.

---

1. Pandemic and Epidemic Disease Department, World Health Organization, Geneva, Switzerland.
2. University of the Philippines-Manila National Institutes of Health, Manila, Philippines.
3. Delivering Oral Vaccine Effectively (DOVE), Johns Hopkins Bloomberg School of Public Health, 615 N Wolfe Street, Baltimore, MD 21205, United States of America (USA).
4. United Nations Children’s Fund, United Nations Plaza, New York, USA.
5. National Institute of Hygiene and Epidemiology, Hanoi, Viet Nam.
6. Epicentre, Paris, France.
7. Correspondence to Jacqueline Deen (email: deen.jacqueline@gmail.com).
8. Submitted: 13 April 2014 – Revised version received: 14 September 2014 – Accepted: 17 September 2014 – Published online: 29 September 2014

Bull World Health Organ 2014;92:881–893 | doi: http://dx.doi.org/10.2471/BLT.14.139949
A comparison of the three oral cholera vaccines is shown in Table 1. The safety, relative effectiveness and duration of protection of the different types of oral cholera vaccine has previously been reviewed. Here we conduct a systematic review of post-licensure oral cholera vaccines. The objective of the review is to generate information – by describing and analysing the campaigns – that can be used to inform planning for the future use of these vaccines.

Methods

Search

We searched the Cochrane database of systematic reviews and its database of abstracts and reviews of effects from 1990 to the present and found no reviews of oral cholera vaccination campaigns.

We conducted a systematic review of published documents on post-licensure vaccination campaigns using one of three oral cholera vaccines following the search and analysis process recommended in the Preferred Reporting Items for Systematic Reviews and Meta-analyses guidelines. We searched PubMed and the WHO website using “cholera vaccination”, “cholera outbreak response” and “cholera vaccination campaign” as search terms with no date or language restrictions. The bibliographies of the retrieved articles were also screened for relevant papers. Reports, presentations and international organization or company documents were obtained through targeted web searches. We also contacted public health personnel, experts in the field and in ministries of health for further information.

All identified documents in English that described campaigns using oral cholera vaccine were assessed for appropriateness using the following selection criteria. We included all documents describing campaigns using Dukoral® after 1991, ORC-Vax™ after 1997, mORC-Vax™ after 2009 and Shanchol™ after 2009. Campaigns organized either as part of a public health response to endemic or epidemic cholera, pilot campaigns, demonstration projects, assessments of feasibility and acceptability, as well as studies of vaccine effectiveness were included. Each campaign may have more than one reference, describing different aspects of the vaccination (e.g. feasibility, coverage, cost, etc.). We excluded documents describing pre-licensure trials, reports on knowledge and perception of cholera and oral cholera vaccines, as well as planning or policy briefs that did not describe actual oral cholera vaccine deployment.

By adhering to the pre-defined inclusion and exclusion criteria, we could make a valid comparison across articles. To assess the broad picture of the vaccine campaigns, we did not exclude any document based on quality or deficiency of reporting. Information from the published and unpublished documents was extracted and entered into a spreadsheet independently by two of the authors and then corroborated and summarized by a third author.

Definitions

Oral cholera vaccine campaigns can either be pre-emptive or reactive. Pre-emptive or preventive vaccination refers to campaign implementation before a cholera outbreak begins, ideally in conjunction with improved water, hygiene and sanitation. Pre-emptive vaccination may be conducted before the next seasonal outbreak in sites where cholera regularly occurs, in communities adjacent to an area with cholera or during humanitarian emergencies to prevent cholera. Reactive campaigns are those implemented after a cholera outbreak has started and while cholera cases are still being detected in the target population. In areas where cholera tends to occur all year-round, the distinction between pre-emptive and reactive vaccination may be difficult.

The target population was defined as the number of individuals living in a circumscribed area to whom oral cholera vaccine is offered. The target population may be an estimate based on administrative population figures or a more precise figure based on a study census. Coverage was defined as the percentage of the target population who received one dose and two doses (fully immunized) of the vaccine, except when otherwise indicated (i.e. community surveys were used to calculate vaccine coverage in some campaigns particularly when a precise target population number was not known). The approximate total number of oral cholera vaccine doses deployed was defined as the sum of the first and second dose recipients; when data on the first dose recipients were not available, we multiplied the number of fully vaccinated individuals by two. We plotted the number of approximate doses deployed in oral cholera vaccine campaigns by country. Countries were colour-coded by the number of cholera cases reported in 2005, using ArcMap 10.0 (ESRI, 2012).
Redlands, USA). Adverse events following immunization were defined as medical incidents that take place after an immunization and cause concern. Adverse events following immunization may be coincidental or causally associated. A serious adverse event following immunization is one that requires hospitalization and/or causes birth defects, permanent damage, or death.

To allow comparison of the expenses for vaccination across various campaigns, the expenses were grouped into the following categories: vaccine and/or international shipment costs, computers and other capital expenses, international consultants, local storage and transport, meetings, social mobilization, training, local salaries, supplies and waste management and the detection and management of adverse events following immunization. The delivery cost per fully immunized person was calculated using the total local expenses (excluding vaccine, international shipment and consultant costs) as the numerator and the number of fully immunized persons as the denominator.

**Results**

We identified 173 unique documents of potential relevance and 33 of these met the inclusion criteria (Fig. 1). In addition, we obtained information about recent campaigns through personal communications with two co-authors (DL and KA). We mapped the approximate number of doses administered in post-licensure oral cholera vaccination campaigns from 1997 to 2014 (Fig. 2) and plotted them by year (Fig. 3). As of August 2014, 280,000 oral cholera vaccine doses from the stockpile were shipped to Ethiopia, 280,000 to Guinea, 400,000 to Haiti and 300,000 to South Sudan. For campaigns with detailed data available, the characteristics and main findings are shown in Table 2 and the vaccination logistics by target population size is shown in Table 3.

**Dukoral®**

About 526,017 doses of Dukoral® were administered in six vaccination campaigns from 1997 to 2009, all of which were pre-emptive (Table 2). These included two feasibility studies in refugee camps and one campaign following a natural disaster. The percentage of fully immunized persons ranged from 50–88%. There were two effectiveness studies in sub-Saharan Africa, which confirmed direct vaccine protection of 78–79%, 12 to 15 months following vaccination, as well as herd protection. We found one document stating that 137,000 Dukoral® doses were delivered to Myanmar in 2008 but we were unable to find more information.

The duration of the vaccination campaigns ranged from one to five months and consisted of two rounds at a 10- to 14-day interval (Table 3). Each round took 4 to 15 days. A cold chain for vaccine delivery was reportedly maintained at 2–8 °C from storage to administration in Aceh, Indonesia; Beira, Mozambique; and Zanzibar, United Republic of Tanzania. In Uganda, the vaccine was maintained at room temperature. Vaccination teams were able to vaccinate 100 to 1735 persons per day. Reported adverse events following immunization in Mozambique and Uganda were minor and non-specific. Delivery cost per fully immunized person ranged from 0.53 United States dollars (US$) to US$ 3.66 (Table 4).

**ORC-Vax™ and mORC-Vax™**

In Viet Nam, an estimated 10.9 million doses of ORC-Vax™ and mORC-Vax™ have been deployed from 1997 to 2013 through targeted mass vaccination or to children – through the Expanded Programme of Immunization in cholera-endemic regions. Documented coverage during the vaccination of half of the communes in Hue was 79% (118,703/149,557) in 1998 and 75% (103,226/137,082) in the other half in 2000; long-term vaccine effectiveness (three to five years after the campaign) was 50%. (Table 2). Vaccine coverage was not precisely quantified in the 2008 Hanoi campaign; vaccine effectiveness was 76%. The duration of the vaccination campaigns ranged from two to four weeks with each round taking 3 to 9 days (Table 3). Mass campaigns are held yearly in Hue and are part of the routine public health provision, requiring minimal additional costs. The delivery cost in Hue during a 2013 campaign was US$ 0.11 per fully immunized person.

**Shanchol™**

Since WHO pre-qualification, Shanchol™ has been increasingly used in campaigns. About 2,649,189 doses have been administered in more than 10 campaigns (Table 2; data from the most recent campaigns in Ethiopia, Guinea and Haiti are not yet available), three of which were described as reactive. The percentage of fully immunized persons ranged from approximately 46–85% (Table 2). A study in Odisha, India 2011, found that oral cholera vaccination through the Indian public health system is feasible. The campaign in Dhaka, Bangladesh 2011, includes an assessment of vaccine effectiveness with and without other interventions. The two vaccination campaigns in Haiti in 2012 were pilot projects that paved the way for the launching of a national...
Fig. 2. Post-licensure oral cholera vaccination campaigns, 1997–2014

Number of vaccines in 2014 counted from January to August.
The Shanchol™ campaigns were integrated in a long-term plan to address water safety and sanitation. There was a third campaign in Haiti in 2013 that was part of this plan. Shanchol™ was deployed for pre-emptive vaccination in the Solomon Islands in 2012, following reports of cholera in a nearby area. The vaccination campaign in Thailand, 2012, was conducted to prevent seasonal outbreaks in a stable camp setting. The vaccination campaign in Thailand, 2012, was the first reactive oral cholera vaccine campaign in sub-Saharan Africa and the first time that Shanchol™ was used in an African setting. The campaigns in Guinea and in Maban county, South Sudan 2013 confirmed that large-scale vaccinations under logistically difficult conditions are feasible. The campaign in internally displaced persons camps in South Sudan in 2014, was the first to use the oral cholera vaccine stockpile. The Shanchol™ campaigns were conducted in 1–3 months. The 2012 Haiti campaign was carried out in two phases due to an overlapping national oral polio vaccination campaign. The number of persons vaccinated per day ranged from 774–1150. No serious adverse events following immunization were reported. In campaigns in Odisha, Dhaka and in Haiti in 2012, acold chain for vaccine was maintained at 2–8 °C from storage to delivery on site. In the campaigns in Guinea and in South Sudan cold chain was maintained until the day of vaccination, during which vaccines were transported to vaccination sites and used at ambient temperature.

The delivery costs of Shanchol™ through the existing government health system in Bangladesh and India were US$ 1.63 and US$ 1.13, respectively, per fully immunized person. The local expenses of reactive deployment in Guinea were US$ 1.97, while costs in Maban, South Sudan were US$ 3.99 per fully immunized person (Table 3).

**Discussion**

We estimate that about 3 175 206 doses of Dukoral™ and Shanchol™ have been deployed in vaccination campaigns in areas affected by cholera around the world from 1997 to 2014. Only one country, Viet Nam, incorporates oral cholera vaccination into its public health programme and has used more than 10 million doses since 1997. Recently larger numbers of doses have been deployed in different areas globally but the vaccine is still under-used compared to the 1.4 billion people at risk of cholera in endemic areas. There is a shortage of licensed, WHO-prequalified cholera vaccines to meet global endemic and epidemic needs and insufficient supply is often cited as an obstacle to wider vaccine use. Availability of an oral cholera vaccine stockpile may lead to a larger vaccine supply through more consistent and predictable demands and may help increase vaccine use. Insufficient vaccine supply can be addressed by encouraging manufacturers to increase production capacity.

The deployments of oral cholera vaccine have previously been pre-emptive but recent experiences in Guinea and Haiti have shown that reactive mass vaccinations are feasible. The number of cases and deaths that can be prevented by reactive vaccination depends on the characteristics of the outbreak, with greatest impact during large and long-lasting outbreaks usually seen in populations with no recent exposure to the disease. With the development of an oral cholera vaccine stockpile and possibility of rapid deployment, increased reactive use of oral cholera vaccine is anticipated.

To be able to compare the campaigns, we calculated the total delivery cost per fully immunized person by excluding the expenditures for vaccine, shipment and technical experts, but the estimates still varied considerably. Deployment costs were lowest in Hue, Viet Nam, where the vaccine is administered routinely through the public health system but a similar delivery strategy may not be possible in other cholera-endemic areas or during the acute phase of emergencies. The requirement for co-administration of a buffer with the Dukoral™ vaccine complicates the delivery of such vaccine and likely increases its delivery costs. Both mORC-Vax™ and Shanchol™ do not require a buffer, which should streamline the delivery and reduce logistical requirements.

This analysis has several limitations. First, there was a wide variation in the methods used to calculate coverage and costs in the vaccination campaigns. Some coverage estimations were precise, while others were approximations. Although we attempted to make the costing comparable, the calculated figures should be interpreted with caution. There are large variations in the costing of some items that cannot merely be explained by differences in site conditions and access. There are also local variables such as distance from central storage to the vaccine administration sites, campaign duration and vaccine storage conditions that affect the costs. Variations in campaign logistics also influence the estimates. Differences may also arise from the methods used to calculate expenses. For future campaigns, estimating cost...
### Table 2. Characteristics and main findings of post-licensure oral cholera vaccination campaign studies, 1997–2014

| Vaccine and year of the campaign | Site | Setting | Type and purpose of the vaccination campaign | Eligibility criteria | Target population | Coverage | Main findings |
|---------------------------------|------|---------|---------------------------------------------|----------------------|------------------|----------|--------------|
|                                 |      |         |                                             |                      |                  | 1st dose, no. (%) | 2nd dose, no. (%) |                |
|                                 |      |         |                                             |                      |                  | (%)      | (%)          |                |
| Dukoral* 1997                   | Adjumani district, Uganda | Refugee camp, rural | Pre-emptive vaccination to assess feasibility in a stable refugee camp setting\(^{16,17}\) | \(\geq 1\) year old | 44,000 | 35,613 (81) | 27,607 (62) | Oral cholera vaccination of a large refugee population is feasible. During a cholera epidemic in the area the following year, cholera attack rates were 0.59% in the non-refugee Ugandan villages, 0.04% in the 30 non-vaccinated refugee camps and 0.00% in the six vaccinated refugee camps\(^{17}\). |
| 2000                            | Mayotte Island, Comoros | Urban and rural | Pre-emptive vaccination campaign to prevent a cholera epidemic\(^{18}\) | NA | 145,000 | NA | 93,000 (64) | NA |
| 2003–2004                       | Beira, Mozambique | Urban | Pre-emptive vaccination in an endemic area with seasonal outbreaks. Effectiveness study in an HIV-endemic sub-Saharan African site\(^{20,21}\) | Non-pregnant women, \(\geq 2\) years old children | 19,550 | 14,164 (72) | 11,070 (57) | Mass vaccination was feasible but required considerable logistic support and planning. One or more doses conferred 78% protection (95% CI: 39–92) against cholera during the year post vaccination\(^{21}\). |
| 2004                            | South Darfur, Sudan | Refugee camp, rural | Pre-emptive vaccination to assess feasibility during the acute phase of an emergency (i.e. refugee camp of internally displaced persons)\(^{22,23}\) | \(\geq 2\) years old | 45,825 | 42,502 (93) | 40,330 (88) | Although planning and implementation requirements were significant, the campaign was successful because of the strong support and commitment of the refugee community and collaborators\(^{22,23}\). |
| 2005                            | Aceh, Indonesia | Site of internally displaced persons | Pre-emptive vaccination to assess feasibility during the acute phase of an emergency (i.e. post-tsunami)\(^{23,24}\) | \(\geq 2\) years old | 78,870 | 62,505 (79) | 54,627 (69) | Challenges in the coordination, heavy logistics and frequent aftershocks complicated and delayed implementation. Difficulties in maintaining a cold chain resulted in 11.7% vaccine losses\(^{23,24}\). |
| 2009                            | Zanzibar, the United Republic of Tanzania | Urban and rural | Pre-emptive vaccination in an endemic area with seasonal outbreaks. Effectiveness study to measure direct and indirect protection\(^{25–28}\) | Non-pregnant women, \(\geq 2\) years old children | 48,178 | 27,678 (57) | 23,921 (50) | Confirmed direct vaccine effectiveness of 79% (95% CI: 47–92). First study to show vaccine herd protection in an African setting: 75% (95% CI: 11–93%) indirect protection in the higher coverage group compared with the lower coverage group. No evidence of a harmful effect of gestational exposure to the vaccine. First use of personal digital assistants for direct data entry during a survey enumeration and mass vaccination\(^{28}\). |

(continues...)
| Year of the campaign | Site | Setting | Type and purpose of the vaccination campaign | Eligibility criteria | Target population | Coverage | Main findings |
|----------------------|------|---------|---------------------------------------------|---------------------|------------------|----------|---------------|
|                      |      |         |                                             |                     |                  |          |               |
| 1998–2012           | Viet Nam | Endemic urban and rural areas | Pre-emptive and reactive vaccinations of children integrated into the country’s public health programme | Non-pregnant women, ≥ 1 year old children | ≈10.9 million doses | NA       | NA | Viet Nam is the only country in the world to regularly use oral cholera vaccinations. Since 1997, the number of cholera cases in Viet Nam has declined, in association with increased vaccination use as well as improvements in socioeconomic and water and sanitation conditions. Mass immunization is feasibly administered through the public health system. Direct vaccine effectiveness 3 to 5 years after vaccination was 50% (95% CI: 9–63). |
| 1998 and 2000       | Hue, Viet Nam | Urban and rural | Pre-emptive vaccination campaign in a cholera-endemic area. Study to assess long term effectiveness | Non-pregnant women, ≥ 1 year old children | 149,557 (1998) and 137,082 (2000) | In 1998: 125,135 (84) and in 2000: 104,706 (76) | In 1998: 118,703 (79) and in 2000: 103,226 (75) | Mass immunization is feasibly administered through the public health system. Direct vaccine effectiveness 3 to 5 years after vaccination was 50% (95% CI: 9–63). |
| 2008               | Hanoi, Viet Nam | Urban | Reactive vaccination campaign during an ongoing outbreak | Non-pregnant women, ≥ 1 year old children | ≈370,000 > 10 years old | NA       | ≈80% vaccinated | Protective effectiveness of 76% (95% CI: 5–94). First study to document reactive use of oral cholera vaccination during an outbreak. |
| 2011               | Odisha, India | Rural | Pre-emptive vaccination campaign and feasibility study | Non-pregnant women, ≥ 1 year old children | 51,488 | 31,552 (61) | 23,751 (46) | Feasible to vaccinate using governmental set-up. |
| 2011               | Dhaka, Bangladesh | Endemic urban areas | Pre-emptive vaccination. Cluster randomized study with three arms: vaccine, vaccine plus safe water and hand washing practice and no intervention | Non-pregnant women, ≥ 1 year old children | 172,754 | 141,839 (82) | 123,666 (72) | Feasible to use the national immunization set-up. Ongoing study of vaccine effectiveness |
| 2012               | Port-au-Prince, Haiti | Urban | Reactive vaccination campaign. Pilot study | ≥ 1 year old children | 70,000 | 52,357 (75) | 47,540 (68) | Effort, community mobilization and organizational capacity needed for a successful campaign where there were logistical and security challenges. |
| 2012               | Bocozel and Grand Saline, Haiti | Rural | Reactive vaccination campaign. Pilot study | ≥ 1 year old children | 50,000 | 45,417 | 41,238 (Estimated 77–79% in Bocozel and 63% in Grand Saline) | The campaign integrated with the other components of cholera control was found to be feasible and acceptable. |
| Vaccine and year of the campaign | Site | Setting | Type and purpose of the vaccination campaign | Eligibility criteria | Target population | Coverage | Main findings |
|---------------------------------|------|---------|---------------------------------------------|---------------------|------------------|----------|--------------|
| 2012                            | Choiseul and Shortland, Solomon Islands | Rural | Pre-emptive vaccination campaign near an area with a cholera outbreak | Children 1–14 years old in high-risk areas | NA | 11 888 | 11 318 | NA |
| 2012                            | Tak Province, Thailand | Refugee camps, rural | Pre-emptive vaccination campaign with a knowledge, attitudes and practices survey | Non-pregnant women, ≥ 1 year old children | 43 968 | 36 325 (83) | 26 753 (61) | First use of Shanchol™ in a stable refugee camp setting |
| 2012                            | Boffa and Forecariah regions, Guinea | Rural | Reactive vaccination campaign during an on-going outbreak and feasibility study | ≥ 1 year old children | =209 000 (=163 000 in Boffa and =46 000 Forecariah) | 172 544 | 143 706 (Based on administrative population figures, 68% in Boffa and 51% in Forecariah. Household survey immediately after campaign 76%) | First use of Shanchol™ in sub-Saharan Africa. The campaign was successful despite short preparation time, remote rural setting and highly mobile population. Protective effectiveness of 87% (95% CI: 56–96) |
| 2013                            | Maban county, South Sudan | Refugee camps, rural | Pre-emptive vaccination campaign in an area with escalating Hep E outbreak | ≥ 1 year old children | 146 317 | NA | 132 000 (> 89% by survey) | The campaign was successful despite logistical challenges |
| 2013                            | Petite Anse and Cerca Carrajal, Haiti | Urban and rural | Pre-emptive vaccination campaign in a cholera-endemic area | ≥ 1 year old children | >110 000 | 113 045 | 102 250 | NA |
| 2014                            | South Sudan Internally displaced persons camps | Internally displaced persons camps | Pre-emptive vaccination campaign | Non pregnant women, ≥ 1 year old children | 152 000 | 125 311 (72) | 76 088 (awaiting coverage surveys) | Humanitarian crisis. First use of global OCV stockpile. Fixed and mobile teams. Second round in one site was co-administered with meningitis vaccine |

CI: confidence interval; Hep E: Hepatitis E; NA: information not available; OCV: oral cholera vaccination.

1 Information obtained through personal communications with Kathryn Alberti, UNICEF, New York, USA.
### Table 3. Logistics of oral cholera vaccination campaigns, 1997–2013

| Target population size | Site, year | Vaccine | Max. days per round | Total duration | Delivery method | Approximate doses delivered/day | Staff |
|------------------------|------------|---------|---------------------|----------------|----------------|-------------------------------|-------|
| < 50,000               | Adjumani district, Uganda, 1997<sup>16</sup> | Dukoral<sup>®</sup> | 4                   | Just over 1 month | 15 vaccination sites | 250–1735 | 114 persons; 19 nurses/midwives, 21 nursing aides, 44 community health workers and 30 persons without qualifications |
|                        | Esturro, Beira, Mozambique, 2003–2004<sup>30</sup> | Dukoral<sup>®</sup> | 9                   | 1 month          | Outposts in churches and schools 08:00–15:00 6 days/week | Average 609 | One supervisor and 15–23 members per outpost |
|                        | Zanzibar, the United Republic of Tanzania, 2009<sup>35</sup> | Dukoral<sup>®</sup> | 15                  | Just over 1 month | Eight vaccination posts on each of the two islands, 8 hours daily | NA | Local health care workers and villagers |
|                        | Aceh, Indonesia, 2005<sup>12,14</sup> | Dukoral<sup>®</sup> | NA                  | 5 months         | Three-phase approach, three different geographical areas with approximately one month between each phase. Fixed vaccination sites with some door-to-door mop-up | 100–250 | 4 members per team |
| 50,000 to 100,000      | Odisha, India, 2011<sup>14</sup> | Shanchol™ | 3                   | 1 month          | Vaccination booths within 10–15 minute walking distance from villagers open 07:00–17:00 daily | NA | At each booth: 1 midwife and 5–6 community health workers/volunteers |
|                        | City of God, Port-au-Prince and Bocozel and Grand Saline, Artibonite Department, Haiti, 2012<sup>29,32</sup> | Shanchol™ | Urban: NA Rural: 10 | 3 months per site | Urban: door-to-door pre-registration and vaccination at 9 fixed sites Rural: fixed posts, mobile posts and door-to-door | NA | Urban campaign: 500 staff, 75 teams of 4 workers, plus 15 supervisors Rural: 40 teams of 4 workers each led by 20 supervisors |
|                        | Viet Nam 1998 and 2000<sup>30,31</sup> | ORC-Vax™ | 9                   | 1 month          | Specifically designated sites, also used by EPI. 90 sites | 139 (max) | 90 teams |
|                        | Viet Nam 2008<sup>32</sup> | ORC-Vax™ | 3                   | 13 days          | Fixed outreach vaccination sites. Sixty vaccine clusters were grouped into five cycles. In each 3-day vaccination cycle, 12 clusters were covered. The teams then moved on to the next cycle and thus all clusters were covered two times in two rounds | NA | NA |
|                        | Mirpur, Dhaka, Bangladesh 2011<sup>35</sup> | Shanchol™ | 3-day cycles | One and half months | Specifically designated sites, also used by EPI. 90 sites | 900–1000 | 76 vaccinators, 220 volunteers and 12 first line supervisors |
| > 100,000              | Boffa and Forecariah regions, Guinea 2012<sup>24,44</sup> | Shanchol™ | 6                   | 3 months         | Decentralized semi-mobile strategy. Most sites in place for only 1 day. In rural areas, teams could cover three sites in one day | 774 (avg) | 43 teams of 9 to 20 people |
|                        | Maban county, South Sudan 2013<sup>46,47</sup> | Shanchol™ | 7                   | Just over 1 month | Semi-mobile strategy, fixed points for first days of round, then mix of fixed sites and mop-up for last days of round. Also, in each MSF clinic | 1150 | Teams of 10 people at each site, plus 14 people per camp for mobilization |

EPI: Expanded Programme on Immunization; MSF: Médecins Sans Frontières; NA. OCV: oral cholera vaccine.
### Table 4. Cost of post-licensure oral cholera vaccinations, 1997–2013

| Characteristic | Uganda, 1997 | Mozambique, 2003–2004 | Indonesia, 2005–2006 | United Republic of Tanzania, 2009 | Bangladesh, 2011 | Guinea, 2011 | South Sudan, 2012 | India, 2011
|----------------|-------------|----------------------|----------------------|-------------------------------|-----------------|-------------|-----------------|-------------
| Oral cholera vaccine | Dukoral® | Dukoral® | Dukoral® | Dukoral® | Shanchol™ | Shanchol™ | Shanchol™ | Shanchol™ |
| Price per vaccine dose, US$ | Free | Free | 4.70 | 5.00 | 2.22 | 1.00 | 1.85 | 2.40 |
| Number fully immunized persons | 607 | 156 | 627 | 921 | 751 | 666 | 706 | 912 |
| Vaccine and/or international shipment costs, US$ | 421 | 608 | 247 | 000 | 629 | 529 | 782 | 690 |
| Computers and other capital expenses, US$ | 600 | 738 | 215 | 081 | 930 | 482 | 340 | 630 |
| International consultants, US$ | NA | NA | 230 | 000 | 917 | 977 | 918 | 766 |
| Local storage and transport, US$ | 239 | 510 | 081 | 930 | 930 | 428 | 930 | 630 |
| Meetings, community mobilization, training, local salaries, and waste management, US$ | 5 | 395 | 269 | 275 | 500 | 625 | 932 | 630 |
| Adverse event following immunization monitoring and management, US$ | 4 | 237 | 237 | 237 | 237 | 237 | 237 | 237 |
| Total local delivery cost (per person), US$ | 890 | 890 | 890 | 890 | 890 | 890 | 890 | 890 |

**Note:**
- NA: not available; US$: United States dollar.
- Including vaccinations outside the study target population.
- Costs originally reported in Euro. US$ was calculated using the conversion rate as of 1 February 2013: 1 Euro to US$ 1.37.

Despite these limitations, our findings provide important lessons. The number of oral cholera vaccination campaigns is increasing and experience has been documented in a variety of settings. The increasing use of oral cholera vaccine is reassuring but more needs to be done to encourage its use where needed. Since the creation of the stockpile, a higher number of doses have been used and this increase will likely continue with the availability of an oral cholera vaccine stockpile and as more experience is gained with campaigns. Data from the deployments confirm the effectiveness, safety and feasibility of mass oral cholera vaccination. While the two-dose vaccination schedule may be perceived as an impediment to delivery and coverage, the experience with both Dukoral® and Shanchol™ disproves this perception. In addition, community education on cholera control and distribution of other preventive measures such as soap and chlorine solution were successfully integrated into recent vaccination campaigns.

---

**Stephanie Martin et al.**

**Oral cholera vaccination campaigns**

Systematic reviews

**Bull World Health Organ** 2014;92:881–893 doi: http://dx.doi.org/10.2471/BLT.14.139949
pursued, supported and published. This will ensure appropriate documentation of future campaigns.

Funding: This research was supported by the World Health Organization and by the Delivering Oral Vaccine Effectively (DOVE) project. DOVE is supported by the Bill & Melinda Gates Foundation and administered through the Johns Hopkins Bloomberg School of Public Health.

Competing interests: None declared.

Systematic reviews

Oral cholera vaccination campaigns

Stephen Martin et al.

Melting

Nurture the oral cholera vaccines after their licencing: a systematic review

Objective

Describe and analyse characteristics of oral cholera vaccination campaigns, focusing on the location, population targeted, logistics, vaccine coverage and delivery costs.

Methods

We searched PubMed, the World Health Organization (WHO) website and Cochrane databases, without any date or language restrictions. We contacted public health personnel and experts and carried out targeted Internet searches.

Results

In total, 33 documents were included. Vietnam included oral cholera vaccination in its public health program and managed about 10.9 million doses between 1997 and 2012. Furthermore, more than 3 million doses of the two prequalified oral cholera vaccines were managed in 166 campaigns around the world between 1997 and 2014. These campaigns have been conducted in various settings, such as refugee camps or natural disasters. The estimated coverage for two doses for the target population was from 46% to 88%. The average cost for a fully vaccinated person was between 0.11 and 3.99 USD.

Conclusion

The experience with oral cholera vaccination campaigns continues to grow. Public health officials can use this experience to more frequently conduct oral cholera vaccination campaigns.

Résumé

Déploiement après homologation des vaccins oraux contre le choléra: une revue systématique

Objectif

Décrire et analyser les caractéristiques des campagnes de vaccination orale contre le choléra; y compris le site, la population cible, la logistique, la couverture vaccinale et les coûts de distribution.

Méthodes

Nous avons effectué des recherches dans PubMed, le site Internet de l’Organisation mondiale de la Santé (OMS) et la base de données Cochrane sans aucune restriction de date ou de langue. Nous avons contacté des membres du personnel de la santé publique, des experts travaillant dans le domaine et dans les ministères de la Santé et nous avons ciblé les recherches sur Internet.

Résultats

Nous avons inclus 33 documents au total dans l’analyse. Un seul pays, le Viêtnam, inclut la vaccination orale anticholérique dans son programme de santé publique et a administré environ 10,9 millions de doses de vaccins entre 1997 et 2012. En outre, plus de 3 millions de doses des deux vaccins oraux anticholériques préévalués par l’OMS ont été administrés dans plus de 16 campagnes de vaccination dans le monde entier entre 1997 et 2014. Ces campagnes ont été menées en prévention ou en réaction et ont eu lieu dans diverses conditions, comme dans des camps de réfugiés ou lors de catastrophes naturelles. La couverture estimée des deux doses était comprise entre 46% et 88% de la population cible. Les frais de distribution approximatifs par personne entièrement vaccinée sont compris entre 0,11 et 3,99 dollars. Conclusion

L’expérience avec les campagnes de vaccination orale contre le choléra continue à se développer. Les responsables de la santé publique peuvent tirer profit de cette expérience et mener plus fréquemment des campagnes de vaccination orale contre le choléra.
Резюме

Постлицензионный опыт применения пероральной противохолерной вакцины: систематический обзор

Цель Описать и проанализировать особенности кампаний по проведению пероральной вакцинации против холеры, включая места проведения, целевые группы населения, логистику, охват вакцинацией и стоимость доставки вакцины.

Методы Поиск был проведен в базах данных PubMed, на сайте Всемирной организации здравоохранения (ВОЗ) и в Коррекционной базе данных без каких-либо ограничений по датам или языкам. Были проведены беседы с сотрудниками органов здравоохранения, экспертами в данной области и в министерствах здравоохранения, а также проведен целенаправленный поиск через поисковые системы в Интернете.

Результаты Всего было проанализировано 33 документа. В одной стране, во Вьетнаме, пероральная вакцинация против холеры является частью программы здравоохранения, и в период с 1997 по 2012 г. было введено приблизительно 10,9 миллиона доз вакцины. Кроме того, более 3 миллионов доз двух пероральных противохолерных вакцин, прошедших предварительную оценку ВОЗ на соответствие требованиям, были введены в ходе более 16 кампаний по всему миру в период с 1997 по 2014 г. Эти кампании носили либо превентивный, либо реактивный характер и проводились в разных условиях, например в лагерях беженцев или на месте природных катастроф. По приблизительным подсчетам по две дозы получили 46–88% целевой группы населения. Приблизительная стоимость доставки в расчете на одного прошедшего полную иммунизацию человека варьировалась в пределах от 0,11 до 3,99 долларов США.

Выход Опыт проведения кампаний по пероральной вакцинации против холеры продолжает накапливаться. Официальные лица органов здравоохранения могут использовать данный опыт и чаще проводить кампании по пероральной вакцинации против холеры.

Resumen

Utilización de vacunas orales contra el cólera posterior a la aprobación de su uso: una revisión sistemática

Objetivo Describir y analizar las características de las campañas de vacunación oral contra el cólera, incluyendo la ubicación, la población objetivo, la logística, los costes de cobertura y la entrega de vacunas.

Métodos Realizamos búsquedas en PubMed, la página web de la Organización Mundial de la salud (OMS) y la base de datos Cochrane sin restricciones de fechas ni idioma. Nos pusimos en contacto con el personal de salud pública, expertos del sector y los ministerios de salud, y realizamos búsqueda específicas en la web.

Resultados Se incluyó un total de 33 documentos en el análisis. Un país, Viet Nam, incorpora vacunas orales contra el cólera en su programa de salud pública y ha administrado aproximadamente 10,9 millones de dosis de vacunas entre 1997 y 2012. Además, se han administrado más de 3 de millones de dosis de las dos vacunas orales contra el cólera que cumplen con los requisitos de la OMS en más de 16 campañas en todo el mundo realizadas entre 1997 y 2014. Estas campañas han sido preventivas o reactivas, y se han llevado a cabo en diversas condiciones, como en campamentos de refugiados o desastres naturales. La cobertura estimada de dos dosis osciló entre el 46 y 88% de la población objetivo. El coste aproximado del suministro por persona completamente inmunizada osciló entre 0,11 y 3,99 dólares de los Estados Unidos.

Conclusión La experiencia con las campañas de vacunación oral contra el cólera sigue aumentando. Los funcionarios de salud pública pueden aprovechar esta experiencia y realizar campañas de vacunación orales contra el cólera con mayor frecuencia.

References

1. Meeting of the Strategic Advisory Group of Experts on immunization, October 2009 – conclusions and recommendations. Wkly Epidemic Rec. 2009;84(50):517–32. PMID: 1999831
2. Martin S, Costa A, Pereira W. Stockpiling oral cholera vaccine. Bull World Health Organ. 2012;90(10):714. doi: http://dx.doi.org/10.2471/BLT.12.114233. PMID: 23109735
3. Clemens JD, Sack DA, Harris JR, Van Loon F, Chakraborty J, Ahmed F, et al. Field trial of oral cholera vaccines in Bangladesh: results from three-year follow-up. Lancet. 1990;335(8684):270–3. doi: http://dx.doi.org/10.1016/S0140-6736(05)73532-2. PMID: 21412922
4. Sanchez JL, Vasquez B, Begue RE, Meza R, Castellares G, Cabezas C, et al. Protective efficacy of oral whole-cell/recombinant-B-subunit cholera vaccine in Peruvian military recruits. Lancet. 1994;344(8932):1273–6. doi: http://dx.doi.org/10.1016/0140-6736(94)90755-2. PMID: 7967990
5. Trach DD, Clemens JD, Ke NT, Thuy HT, Son ND, Canh DG, et al. Field trial of a locally produced, killed, oral cholera vaccine in Vietnam. Lancet. 1997;349(9047):231–5. doi: http://dx.doi.org/10.1016/S0140-6736(96)01297-6. PMID: 10149009
6. Trach DD, Cam PD, Ke NT, Rao MR, Dinh D, Hang PV, et al. Investigations into the safety and immunogenicity of a killed oral cholera vaccine developed in Viet Nam. Bull World Health Organ. 2002;80(1):2–8. PMID: 11884967
7. National EPI Review Report: Vietnam – 30 March to 10 April 2009. Ha Noi: National Institute of Health; 2009. Available from: http://www.unicef.org/vietnam/EPI_NATIONAL_Review_Report_Vietnam_2009_Final.pdf [cited 2013 Aug 6].
8. Sur D, Lopez AL, Kanungo S, Paisley A, Manna B, Ali M, et al. Efficacy and safety of a modified killed-whole-cell oral cholera vaccine in India: an interim analysis of a cluster-randomised, double-blind, placebo-controlled trial. Lancet. 2009;374(9697):1694–702. doi: http://dx.doi.org/10.1016/S0140-6736(09)61297-6. PMID: 19819004
9. Sur D, Kanungo S, Sah B, Manna B, Ali M, Paisley AM, et al. Efficacy of a low-cost, inactivated whole-cell oral cholera vaccine: results from 3 years of follow-up of a randomized, controlled trial. PLoS Negl Trop Dis. 2011;5(10):e1289. doi: http://dx.doi.org/10.1371/journal.pntd.0001289. PMID: 22028938
10. Bhattacharya SK, Sur D, Ali M, Kanungo S, You YA, Manna B, et al. 5-year efficacy of a bivalent killed whole-cell oral cholera vaccine in Kolkata, India: a cluster-randomised, double-blind, placebo-controlled trial. Lancet Infect Dis. 2013;13(12):1050–6. doi: http://dx.doi.org/10.1016/S1473-3099(13)70273-1. PMID: 24140390
11. Clemens J, Shin S, Sur D, Nair GB, Holmgren J. New-generation vaccines against cholera. Nat Rev Gastroenterol Hepatol. 2011;8(12):701–10. doi: http://dx.doi.org/10.1038/nrgastro.2011.174. PMID: 22064524
12. Pena D. Vietnam develops world’s best cholera vaccine. People’s World. 2009 Jun 5. New York: Long View Publishing Co; 2009. Available from: http://www.peoplesworld.org/vietnam-develops-world-s-best-cholera-vaccine/ [cited 2013 Aug 6].
13. Sinclair D, Abba K, Zaman K, Qadiri F, Graves PM. Oral vaccines for preventing cholera. Cochrane Database Syst Rev. 2011;3(3):CD008603. PMID: 21412922
Cholera in disasters: do vaccines prompt new hopes? Expert Rev Vaccines. 2005;4(5):733–7. doi: http://dx.doi.org/10.1586/14760584.4.5.733 PMID: 15728808

Use of the two-dose oral cholera vaccine in the context of a major natural disaster: Report of a vaccination campaign in Aceh Province, Indonesia. Geneva: World Health Organization; 2005.

Oo KN, Aung WW, Thaw HM, Htun MM, Aye KS, Kyaw MF, et al. Coverage and side-effects of oral cholera vaccine (Dukoral vaccine) in Department of Medical Research (Lower Myanmar). Myanmar Health Sci Res J. 2011;23:63–4.

Khatib AM, Ali M, von Seidlein L, Kim DR, Hashim R, Reyburn R, et al. Effectiveness of an oral cholera vaccine in Zanzibar: findings from a mass vaccination campaign and observational cohort study. Lancet Infect Dis. 2012;12(10):735–44. doi: http://dx.doi.org/10.1016/S1473-3099(12)70196-2 PMID: 22954655

Hashim R, Khatib AM, Enwere G, Park JK, Reyburn R, Ali M, et al. Safety of the recombinant cholera toxin B subunit, killed whole-cell (bBS-WC) oral cholera vaccine in pregnancy. PLoS Negl Trop Dis. 2012;6(7):e1743. doi: http://dx.doi.org/10.1371/journal.pntd.0001743 PMID: 22840772

Ali M, Deen JJ, Khatib A, Enwere G, von Seidlein L, Reyburn R, et al. Paperless registration during survey enumerations and large oral cholera mass vaccination in Zanzibar, the United Republic of Tanzania. Bull World Health Organ. 2010;88(7):556–9. doi: http://dx.doi.org/10.2471/BLT.0907334 PMID: 20661976

Schacht C, Weiss MG, Ali SM, Chaignat CL, Khatib AM, Reyburn R, et al. Costs of illness due to cholera, costs of immunization and cost-effectiveness of an oral cholera mass vaccination campaign in Zanzibar. PLoS Negl Trop Dis. 2012;6(10):e1844. doi: http://dx.doi.org/10.1371/journal.pntd.0001844 PMID: 23056660

Vu DT, Hossain MM, Nguyen DS, Nguyen TH, Rao MR, Do GC, et al. Coverage and costs of mass immunization of an oral cholera vaccine in Vietnam. J Health Popul Nutr. 2003;21(4):304–8. PMID: 15043004

Thiem VD, Deen JJ, von Seidlein L, Canh G, Ayh DD, Park JK, et al. Long-term effectiveness against cholera of oral killed whole-cell vaccine produced in Vietnam. Vaccine. 2006;24(20):4297–303. doi: http://dx.doi.org/10.1016/j.vaccine.2006.03.008 PMID: 16830760

Anh DO, Lopez AL, Thiem VD, Dang NT, Duong TN, Park JK, et al. Use of oral cholera vaccines in an outbreak in Vietnam: a case control study. PLoS Negl Trop Dis. 2011;5(1):e1000532. doi: http://dx.doi.org/10.1371/journal.pntd.0000532 PMID: 21283614

Ali M, Lopez AL, You YA, Kim YE, Sah B, Maskery B, et al. The global burden of cholera. Bull World Health Organ. 2012;90(3):209–218. http://dx.doi.org/10.2471/BLT.11.093427 PMID: 2262176

Legros D, Paquet C, Perea W, Marti J, Mugasikha NK, Royer H, et al. Mass vaccination with a two-dose oral cholera vaccine in a refugee camp. Bull World Health Organ. 1999;77(1):10–7. PMID: 10593032

Dorlencourt F, Legros D, Paquet C, Neira M, Ivanoff B, Le Saout E. Effectiveness of mass vaccination with WC/BS cholera vaccine during an epidemic in Adjumani district, Uganda. Bull World Health Organ. 1999;77(1):99–50. PMID: 10612895

Cruvellier wards off cholera threat in Myanmar and Zanzibar [Internet]. Leiden: Crucell; 2009. Available from: http://www.cruccell.com/feature_cholera_vaccination_campaigns. [cited 2014 Sep 26.]

Olsson L, Partment PA-P. Present and future cholera vaccines. Expert Rev Vaccines. 2006;5(6):751–2. doi: http://dx.doi.org/10.1586/14760584.5.6.751 PMID: 17184213

Cavallier P, Lucas M, Perroud V, McChesney M, Ampoure S, Guérin PJ, et al. Feasibility of a mass vaccination campaign using a two-dose oral cholera vaccine in an urban cholera-endemic setting in Mozambique. Vaccine. 2006;24(28):4890–5. doi: http://dx.doi.org/10.1016/j.vaccine.2005.10.006 PMID: 16298025

Lucas ME, Deen JL, von Seidlein L, Wang XY, Ampoure J, Puri M, et al. Effectiveness of mass oral cholera vaccine in Beira, Mozambique. N Engl J Med. 2005;352(8):757–67. doi: http://dx.doi.org/10.1056/NEJMoa043232 PMID: 15728808

Darfur disease outbreak control bulletin. 2004 Aug 15. Geneva: World Health Organization, 2004. Available from: www.who.int/disasters/report/41372.pdf [cited Aug 26, 2014].

Chaignat CL, Monti V, Soepardi J, Petersen G, Soeren E, Naraan J, et al. Cholera in disasters: do vaccines prompt new hopes? Expert Rev Vaccines. 2008;5(8):431–5. doi: http://dx.doi.org/10.1586/14760584.7.4.431 PMID: 18444890

Use of the two-dose oral cholera vaccine in the context of a major natural disaster: Report of a vaccination campaign in Aceh Province, Indonesia. Geneva: World Health Organization; 2005.

Oo KN, Aung WW, Thaw HM, Htun MM, Aye KS, Kyaw MF, et al. Coverage and side-effects of oral cholera vaccine (Dukoral vaccine) in Department of Medical Research (Lower Myanmar). Myanmar Health Sci Res J. 2011;23:63–4.

Khatib AM, Ali M, von Seidlein L, Kim DR, Hashim R, Reyburn R, et al. Effectiveness of an oral cholera vaccine in Zanzibar: findings from a mass vaccination campaign and observational cohort study. Lancet Infect Dis. 2012;12(8):437–44. doi: http://dx.doi.org/10.1016/S1473-3099(12)70196-2 PMID: 22954655

Ciglenecki I, Sakoba K, Luquero FJ, Heile M, Itama C, Mengel M, et al. Acceptability and surveillance of adverse events, Guinea, 2012. PLoS Negl Trop Dis. 2013;7(11):e2576. doi: http://dx.doi.org/10.1371/journal.pntd.0002576 PMID: 24278498

Teng JE, Thomson DR, Lascher JS, Raymond M, Ivers LC. Using Mobile Health (mHealth) and geospatial mapping technology in a mass campaign for reactive oral cholera vaccination in rural Haiti. PLoS Negl Trop Dis. 2014;8(7):e3050. doi: http://dx.doi.org/10.1371/journal.pntd.0003050 PMID: 25078790

Date K, Pharee C. OCV project in Thailand. In: Vaccines For Enteric Diseases; 2013 Nov 6–8; Bangkok, Thailand.

Luquero FJ, Grout L, Ciglenecki I, Sakoba K, Traore B, Heile M, et al. First outbreak response using an oral cholera vaccine in Africa: vaccine coverage, acceptability and surveillance of adverse events, Guinea, 2012. PLoS Negl Trop Dis. 2013;7(10):e2465. doi: http://dx.doi.org/10.1371/journal.pntd.0002465 PMID: 24147164

Ciglenecki I, Sakoba K, Luquero FJ, Heile M, Itama C, Mengel M, et al. Feasibility of mass vaccination campaign with oral cholera vaccines in response to an outbreak in Guinea. PLoS Med. 2013;10(9):e1001512. doi: http://dx.doi.org/10.1371/journal.pmed.1001512 PMID: 24058301

Luquero FJ, Grout L, Ciglenecki I, Sakoba K, Traore B, Heile M, et al. Use of Vibrio cholerae vaccine in an outbreak in Guinea. N Engl J Med. 2014;370(22):2111–20. doi: http://dx.doi.org/10.1056/NEJMoa1312680 PMID: 24869721

Mass oral cholera vaccination campaign (OCV) in Maban County in the refugee camps and host population in the direct surroundings of the camps. Implementation, feasibility, coverage and acceptability. Amsterdam: Médecins Sans Frontières; 2013.

Conan N, Lenglet A. Vaccination coverage with Oral Cholera Vaccine (OCV), Maban County, South Sudan. December 2012–February 2013: Survey report. Amsterdam: Médecins Sans Frontières; 2013.

Oral cholera vaccine campaign among internally displaced persons in South Sudan. Wkly Epidemiol Rec. 2014;89(20):214–20. PMID: 24864347

Oral Cholera Vaccine stockpile for cholera emergency response. Geneva: World Health Organization; 2013. Available from: http://www.who.int/cholera/vaccines/Briefing_OCV_stockpile.pdf [cited 2014 Sep 26].